Skip to Content

Nplate Approval History

Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Development History and FDA Approval Process for Nplate

Aug 22, 2008Approval FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP
Jul 15, 2008Amgen's FDA Nplate Approval Statement Retracted
Jul 14, 2008FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP
Mar 13, 2008Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
Mar 12, 2008Amgen to Discuss Romiplostim Application at FDA ODAC Meeting

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.